Terms: = Prostate cancer AND MAP2K1, MAPKK1, 5604, ENSG00000169032, Q02750, MEK1, MKK1, PRKMK1 AND Treatment
27 results:
1. Rhizochalinin Exhibits Anticancer Activity and Synergizes with EGFR Inhibitors in Glioblastoma In Vitro Models.
Dyshlovoy SA; Hauschild J; Venz S; Krisp C; Kolbe K; Zapf S; Heinemann S; Fita KD; Shubina LK; Makarieva TN; Guzii AG; Rohlfing T; Kaune M; Busenbender T; Mair T; Moritz M; Poverennaya EV; Schlüter H; Serdyuk V; Stonik VA; Dierlamm J; Bokemeyer C; Mohme M; Westphal M; Lamszus K; von Amsberg G; Maire CL
Mol Pharm; 2023 Oct; 20(10):4994-5005. PubMed ID: 37733943
[TBL] [Abstract] [Full Text] [Related]
2. SOX9 in prostate cancer is upregulated by cancer-associated fibroblasts to promote tumor progression through HGF/c-Met-FRA1 signaling.
Qin H; Yang Y; Jiang B; Pan C; Chen W; Diao W; Ding M; Cao W; Zhang Z; Chen M; Gao J; Zhao X; Qiu X; Guo H
FEBS J; 2021 Sep; 288(18):5406-5429. PubMed ID: 33705609
[TBL] [Abstract] [Full Text] [Related]
3. A Multifunctional Therapy Approach for cancer: Targeting Raf1- Mediated Inhibition of Cell Motility, Growth, and Interaction with the Microenvironment.
Zhang L; Pattanayak A; Li W; Ko HK; Fowler G; Gordon R; Bergan R
Mol Cancer Ther; 2020 Jan; 19(1):39-51. PubMed ID: 31582531
[TBL] [Abstract] [Full Text] [Related]
4. L-securinine inhibits cell growth and metastasis of human androgen-independent prostate cancer DU145 cells via regulating mitochondrial and AGTR1/MEK/ERK/STAT3/PAX2 apoptotic pathways.
Zhang D; Liu H; Yang B; Hu J; Cheng Y
Biosci Rep; 2019 May; 39(5):. PubMed ID: 30975734
[TBL] [Abstract] [Full Text] [Related]
5. MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer.
Nickols NG; Nazarian R; Zhao SG; Tan V; Uzunangelov V; Xia Z; Baertsch R; Neeman E; Gao AC; Thomas GV; Howard L; De Hoedt AM; Stuart J; Goldstein T; Chi K; Gleave ME; Graff JN; Beer TM; Drake JM; Evans CP; Aggarwal R; Foye A; Feng FY; Small EJ; Aronson WJ; Freedland SJ; Witte ON; Huang J; Alumkal JJ; Reiter RE; Rettig MB
Prostate Cancer Prostatic Dis; 2019 Dec; 22(4):531-538. PubMed ID: 30804427
[TBL] [Abstract] [Full Text] [Related]
6. Targeted regulation of miR-195 on map2k1 for suppressing ADM drug resistance in prostate cancer cells.
Zhang JY; Li YN; Mu X; Pan ZL; Liu WB
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8599-8608. PubMed ID: 30575899
[TBL] [Abstract] [Full Text] [Related]
7. MiR-203 over-expression promotes prostate cancer cell apoptosis and reduces ADM resistance.
Chen LZ; Ding Z; Zhang Y; He ST; Wang XH
Eur Rev Med Pharmacol Sci; 2018 Jun; 22(12):3734-3741. PubMed ID: 29949147
[TBL] [Abstract] [Full Text] [Related]
8. Propagation of human prostate cancer stem-like cells occurs through EGFR-mediated ERK activation.
Rybak AP; Ingram AJ; Tang D
PLoS One; 2013; 8(4):e61716. PubMed ID: 23620784
[TBL] [Abstract] [Full Text] [Related]
9. Angiotensin II up-regulates PAX2 oncogene expression and activity in prostate cancer via the angiotensin II type I receptor.
Bose SK; Gibson W; Giri S; Nath N; Donald CD
Prostate; 2009 Sep; 69(12):1334-42. PubMed ID: 19517575
[TBL] [Abstract] [Full Text] [Related]
10. [The role of mitogen-activated protein kinase cascades in inhibition of proliferation in human prostate carcinoma cells by raloxifene: an in vitro experiment].
Zhang YX; Kong CZ
Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(4):271-5. PubMed ID: 18361842
[TBL] [Abstract] [Full Text] [Related]
11. Kaempferol and quercetin stimulate granulocyte-macrophage colony-stimulating factor secretion in human prostate cancer cells.
Bandyopadhyay S; Romero JR; Chattopadhyay N
Mol Cell Endocrinol; 2008 Jun; 287(1-2):57-64. PubMed ID: 18346843
[TBL] [Abstract] [Full Text] [Related]
12. hPEBP4 resists TRAIL-induced apoptosis of human prostate cancer cells by activating Akt and deactivating ERK1/2 pathways.
Li H; Wang X; Li N; Qiu J; Zhang Y; Cao X
J Biol Chem; 2007 Feb; 282(7):4943-4950. PubMed ID: 17178731
[TBL] [Abstract] [Full Text] [Related]
13. Human chorionic gonadotropin modulates prostate cancer cell survival after irradiation or HMG CoA reductase inhibitor treatment.
Yacoub A; Hawkins W; Hanna D; Young H; Park MA; Grant M; Roberts JD; Curiel DT; Fisher PB; Valerie K; Grant S; Hagan MP; Dent P
Mol Pharmacol; 2007 Jan; 71(1):259-75. PubMed ID: 17050804
[TBL] [Abstract] [Full Text] [Related]
14. Tumor suppressor activity of glucocorticoid receptor in the prostate.
Yemelyanov A; Czwornog J; Chebotaev D; Karseladze A; Kulevitch E; Yang X; Budunova I
Oncogene; 2007 Mar; 26(13):1885-96. PubMed ID: 17016446
[TBL] [Abstract] [Full Text] [Related]
15. mek1/2 inhibition promotes Taxotere lethality in mammary tumors in vivo.
Yacoub A; Gilfor D; Hawkins W; Park MA; Hanna D; Hagan MP; Curiel DT; Fisher PB; Grant S; Dent P
Cancer Biol Ther; 2006 Oct; 5(10):1332-9. PubMed ID: 16957420
[TBL] [Abstract] [Full Text] [Related]
16. Involvement of c-Jun N-terminal kinase in G2/M arrest and caspase-mediated apoptosis induced by sulforaphane in DU145 prostate cancer cells.
Cho SD; Li G; Hu H; Jiang C; Kang KS; Lee YS; Kim SH; Lu J
Nutr Cancer; 2005; 52(2):213-24. PubMed ID: 16201852
[TBL] [Abstract] [Full Text] [Related]
17. Genistein modulates prostate epithelial cell proliferation via estrogen- and extracellular signal-regulated kinase-dependent pathways.
Wang X; Clubbs EA; Bomser JA
J Nutr Biochem; 2006 Mar; 17(3):204-10. PubMed ID: 16198100
[TBL] [Abstract] [Full Text] [Related]
18. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells.
Pandini G; Mineo R; Frasca F; Roberts CT; Marcelli M; Vigneri R; Belfiore A
Cancer Res; 2005 Mar; 65(5):1849-57. PubMed ID: 15753383
[TBL] [Abstract] [Full Text] [Related]
19. [Effects of P2Y receptor activation on prostatic cancer cells requiring ERK1/2 or p38 cascade].
Chen L; Fang WG; Heng WJ; You JF
Zhonghua Bing Li Xue Za Zhi; 2004 Apr; 33(2):146-50. PubMed ID: 15132853
[TBL] [Abstract] [Full Text] [Related]
20. Sequence dependent exposure of mammary carcinoma cells to Taxotere and the mek1/2 inhibitor U0126 causes enhanced cell killing in vitro.
Yacoub A; Han SI; Caron R; Gilfor D; Mooberry S; Grant S; Dent P
Cancer Biol Ther; 2003; 2(6):670-6. PubMed ID: 14688474
[TBL] [Abstract] [Full Text] [Related]
[Next]
